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Reduced Body Weight, Adipose Tissue, and Leptin Levels
Despite Increased Energy Intake in Female Mice
Lacking Acylation-Stimulating Protein*
IAN MURRAY, PETER J. HAVEL, ALLAN D. SNIDERMAN, AND
KATHERINE CIANFLONE
Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Center, Montre´al,
Que´bec, Canada H3A 1A1; and the Department of Nutrition, University of California (P.J.H.), Davis,
California 95616
ABSTRACT
Acylation-stimulating protein (ASP) is a potent lipogenic protein
produced by adipocytes. In vitro studies have shown that ASP in-
creases triglyceride synthesis and glucose transport in both murine
and human adipocytes. Our initial study indicated that complement
C3-deficient (2/2) mice (and, therefore, ASP deficient) demonstrated
altered dietary postprandial triglyceride clearance. In the present
study we examined the phenotype of female mice longitudinally on
different diets. Female C3(2/2) mice on both low (10% of energy) and
high (40% of energy) fat diets displayed an average reduction in total
body weight of 10.1 6 0.5% (P , 0.0003, by ANOVA) compared with
the C3(1/1) littermates. Reductions in white adipose tissue mass
accounted for most of this weight difference (59% reduction; P , 0.01
on low fat diet). Plasma leptin levels were significantly reduced in
C3(2/2) mice on both high (P , 0.001) and low fat diets (P , 0.01).
This reduction was significant even after adjusting for the reduced
body weight and body fat (P , 0.001). Leptin reductions in the
C3(2/2) were greater on the high fat diet and were associated with
increased food intake (18 6 2% increase; P , 0.001). Furthermore,
there was a decrease in basal glucose levels and basal insulin levels
[12.8% decrease in glucose at 14 weeks (HF; P , 0.05) and 41%
decrease in insulin at 26 weeks (HF; P , 0.05)]. These in vivo ex-
periments demonstrate that female mice lacking ASP have marked
alterations of body weight, adiposity, plasma leptin, and plasma in-
sulin levels. Decreased adiposity and leptin levels occurred in the
ASP-deficient animals despite increased energy intake, suggesting
that energy expenditure was elevated in these animals. Thus, ASP
appears to have an important role in the regulation of energy balance
in mice. (Endocrinology 141: 1041–1049, 2000)
ACYLATION-STIMULATING protein (ASP) stimulatesboth adipocyte fatty acid esterification into triglycer-
ide and glucose transport (reviewed in Ref. 1). This occurs via
an increase in diacylglycerol acyltransferase activity (2) and
translocation of glucose transporters (GLUT1, GLUT3, and
GLUT4) from intracellular sites to the cell surface (3, 4). These
dual effects are mediated through specific cell surface bind-
ing (5, 6), resulting in activation of a signaling pathway that
includes protein kinase C (7). In addition to stimulation of
fatty acid esterification, ASP has recently been shown to also
inhibit hormone-sensitive lipase in adipocytes, indepen-
dently and additively to insulin (8). The major site of action
of ASP appears to be on adipocytes, as determined by com-
petitive binding, stimulation of triglyceride synthesis, and
enhanced glucose transport and transporter translocation
(reviewed in Ref. 1). There is also a differentiation-specific
increase in ASP binding and ASP response in adipocytes (1).
ASP is identical to complement C3adesArg. Cleavage of
complement C3 through the alternate complement pathway
via the interaction of C3, factor B, and adipsin generates C3a
(9). Rapid cleavage of the C-terminal arginine by car-
boxypeptidase N generates ASP (9). Adipocytes are one of
the few cells capable of producing all three of the factors
(factor B, adipsin, and C3) that are required for the produc-
tion of ASP (10, 11). ASP production increases consequent to
adipocyte differentiation (10, 12) and also after chylomicron
stimulation in vitro in adipocytes (13, 14). In vivo arterial-
venous gradients across a sc adipose tissue bed in humans
demonstrate postprandial production of ASP (15), and
plasma ASP levels are elevated in obesity (16, 17). The post-
prandial increase in ASP is adipose tissue specific and is not
observed in the general circulation (15, 18) or in arterial
venous differences across muscle tissue (our unpublished
observations).
The correlation between in vivo postprandial arterial-
venous adipose tissue ASP production associated with di-
etary triglyceride clearance and in vitro functionality data
with chylomicron-stimulated ASP production suggests that
ASP might play an important role in dietary fat clearance and
tissue deposition. Our initial studies in murine models with
excess exogenous ASP confirm this. Administration of ASP
to C57BL/6 mice resulted in decreased plasma triglyceride
levels after an orally administered fat load (19). This increase
in triglyceride clearance was dependent on the degree of
postprandial lipemia (19). Initial studies were performed in
complement C3 knockout mice (20), which lack circulating
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plasma C3 and complement activity (21). Being deficient in
C3, these mice are unable to produce ASP. In young male
mice (129Sv 3 C57BL/6 strain), although fasting triglyceride
levels were not different from those in wild-type littermates,
elevated triglyceride levels were observed postprandially
after an oral fat load, suggesting delayed triglyceride clear-
ance in the absence of ASP (22). Furthermore, administration
of exogenous ASP to these functional ASP knockout male
mice was able to reduce this postprandial lipemia and de-
crease plasma triglyceride levels (22). The female mice dis-
played similar, but less striking, differences in postprandial
lipid metabolism (22).
Like ASP, leptin is produced by adipocytes (23) and is
involved in the regulation of body fat stores. Leptin produc-
tion is regulated by insulin responses to meals (24), an effect
that appears to involve increased adipocyte glucose metab-
olism (25). Leptin is critically involved in the regulation of
body energy balance via its central actions on food intake and
energy expenditure (26). However, leptin also appears to
have peripheral actions on substrate fluxes in the liver (27)
and may act directly on adipocytes (28, 29), where it has been
reported to increase lipolysis and impair insulin-mediated
lipogenesis. Therefore, leptin and ASP may have opposing
effects on adipocyte triglyceride stores. It is possible that ASP
and leptin interact in a paracrine fashion to directly regulate
adipocyte metabolism. In the present study longitudinal ex-
periments were conducted to examine the effects of age and
diet on adipose stores, energy intake, and circulating leptin
and insulin levels in female mice that are functionally defi-
cient in ASP due to genetic knockout of the C3 gene.
Materials and Methods
Ethics
All experimental protocols were approved by the Royal Victoria
Hospital animal care committee and were in accordance with the guide-
lines set out by the Canadian committee on animal care.
Mice
Drs. H. Colten and R. H. Wetsel provided the knockout and wild-type
mice for breeding. Development of the complement C3 knockout has
been described previously in detail (20, 21). The mice were of (129Sv 3
C57BL/6) strain, and heterozygous mating produced the littermates
[wild-type C3(1/1) and knockout C3(2/2)] used for the present ex-
periments. Mice were housed in sterile barrier facilities with equal day/
night periods. In all cases paired littermates were used for the study to
randomize genetic variation.
Genotyping
For genotyping, tail DNA was extracted, and PCR was performed.
PCR was performed using 800 nm each of the following primers: C3
sense, CTT AAC TGT CCC ACT GCC AAG AAA CCG TCC CAG ATC;
C3 antisense, CTC TGG TCC CTC CCT GTT CCT GCA CCA GGG ACT
GCC CAA AAT TTC GCA AC; neomycin sense, ATC GCA TCG AGC
GAG CAC GTA CTC GGA; and neomycin antisense, AGC TCT TCA
GCA ATA TCA CGG CTA GCC. PCR conditions were: 30 cycles at 94
C for 1 min, 67 C for 2 min, and 72 C for 3 min. Products were separated
by electrophoresis on a 7% polyacrylamide gel and visualized with
ethidium bromide staining.
Diet, feeding, and weighing
C3(1/1) and C3(2/2) female mice were weighed once weekly from
weaning at 4 weeks of age. At 8 weeks, the mice were housed individ-
ually and allowed to acclimatize for 2 weeks. At 10 weeks of age, the mice
were placed on pelleted low fat diet (LF) consisting of 19.3% protein,
67.3% carbohydrates, and 4.3% fat (wt/wt/wt) or high fat diet (HF) of
22.9% protein, 45.8% carbohydrate, and 20.3% fat (wt/wt/wt) modified
from the report by Van Heek et al. (30) and obtained from Research Diets,
Inc. (New Brunswick, NJ; diets D12477 and D12478, respectively). The
diets contained 10% Cal (LF) and 40% Cal (HF) energy from fat, with a
1:1:1 ratio of saturated/monounsaturated/polyunsaturated fat and
were stored at 4 C. Carbohydrate was in the form of cornstarch rather
than sucrose (70% LF and 40% HF Cal). The vitamin and mineral content
conformed with the American Institutes for Nutrition guidelines. The
food was weighed twice weekly over a period of 16 weeks, and food
intake was determined over the time period of 10–26 weeks of age.
Plasma assays
Blood was collected at 10, 14, 26, 32, and 48 weeks of age into EDTA-
containing tubes by tail bleeding as previously described (19, 22) from
mice fasted overnight (16 h) with water ad libitum. Blood was separated
by centrifugation and stored at 280 C. Leptin was measured using a
mouse leptin RIA assay (Linco Research, Inc., St. Charles, MO) as de-
scribed by Ahren et al. (31). Fasting insulin was measured using a rat
insulin RIA kit, which has 100% cross-reactivity to mouse insulin (as
described by the manufacturer, Linco Research, Inc.). Glucose was mea-
sured using a Trinder glucose kit (Sigma, St. Louis, MO). Plasma non-
esterified fatty acids, cholesterol and triglyceride were measured using
colorimetric enzymatic kits (Roche, Laval, Canada).
Fat load
After an overnight fast (16 h), 400 ml olive oil (followed by 100 ml air
above the oil) was given by gastric gavage using a feeding tube (12-cm
curved ball tipped feeding needle (20) according to standard procedures
as previously described (19, 22) and similar to previously published
methods (32–35). There was a 2-week interval between the fasting blood
sample and the fat load. Blood (40 ml) was collected at 0, 1, 2, 3, 4, and
6 h by tail bleeding.
Glucose load
For glucose tolerance tests, mice were fasted overnight for 16 h with
water ad libitum. Basal blood was taken (80 ml), and mice were then
injected ip with a sterile d-glucose solution in saline and 2 mg/g BW
from a stock solution of 200 mg/ml (0.010 ml/g BW). Blood was col-
lected by tail bleeding at 0,15, 30, 60, 90, and 120 min (80 ml at 0, 30, 60,
and 120 min for insulin and glucose, 20 ml at 15 and 90 min for glucose
only).
Tissues
Mice were anaesthetized (0.01 ml/10 g BW, im) with a cocktail com-
posed of 5 ml ketamine (100 mg/ml), 2.5 ml xylazine (20 mg/ml), 1 ml
acepromazine (10 mg/ml), and 1.5 ml sterile saline. Blood was drawn
(0.5 ml) by tail bleeding, and the mice were killed by cervical dislocation.
Tissues were dissected, weighed, and frozen in liquid nitrogen. Four
adipose tissues depots were collected: inguinal, pectoral (together with
suprascapular), gonadal (up to the apex of the ovary) and perirenal (with
the adrenal gland removed). Additional tissues collected were heart,
liver, intrascapular and scapular brown adipose tissue, both kidneys and
quadriceps muscles with all visible fat removed.
Fecal analysis
The fat content of the feces was analyzed as described previously (36).
The animals were placed in a chamber with a metabolic screen, and feces
were collected over 24 h on normal chow (6% fat) or collected for 24 h
after a fat load (6 h) with 6 h fasting, followed by food ad libitum. The
stool was weighed and dried to constant weight, and the fat was ex-
tracted as described by Schwartz (36).
Statistical analyses
Results are presented as the mean 6 sem. The two groups were
compared by repeated measures two-way ANOVA followed by Bon-
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ferroni post test (where indicated), t test, or Pearson’s correlation using
computer-assisted analysis (SigmaStat, Jandel Scientific, San Rafael, CA;
and Prism, GraphPad Software, Inc., San Diego, CA).
Results
In this study of female C3(1/1) and C3(2/2) mice,
growth curves were measured from 4–26 weeks of age. Spe-
cific diets were fed from the age of 10 weeks on: LF: C3(2/2),
n 5 12; C3(1/1), n 5 8; and HF: C3(2/2), n 5 11; C3(1/1),
n 5 6. On the LF diet (Fig. 1 left panel), the C3(2/2) mice
weighed 10.9 6 0.5% less (P , 0.0001, by ANOVA), and this
occurred primarily after 9 weeks of age (after puberty) and
maturation of the fat pad [6 weeks cited by Shimomura (37)].
The results for the HF diet are also shown in Fig. 1 (right
panel). Average weight gains in the knockout and wild-type
mice (4 weeks to 25 weeks) were similar and greater than that
in mice on the LF diet [11.5 6 2.0% more in C3(1/1) and
20.5 6 3.9% more in C3(2/2)]. Nonetheless, even on the
high fat diet, the C3(2/2) mice weighed significantly less
(29.3 6 0.4%; P , 0.0003).
To investigate which body tissues were responsible for this
reduced weight, after 4 months on specific diets, tissues were
collected from a subset of both genotypes and diets at 32 and
48 weeks of age. As shown in Fig. 2, at 32 weeks in C3(2/2)
mice there were marked decreases in white adipose tissue
depots on both LF (left panel) and HF (right panel) consistent
with the decrease in body weight [27.9 6 1.0 C3(2/2) vs.
34.2 6 2.3 C3(1/1) g]. There were no significant changes in
liver, kidney, brown adipose tissue, or heart weights. The
total adipose tissue weight (sum of all four adipose depots,
excluding brown adipose tissue) was decreased by 59% on
LF [1.78 6 0.27 C3(2/2) vs. 4.34 6 1.0 C3(1/1)] and by 40%
on HF [6.29 6 1.28 C3 (2/2) vs. 10.41 6 0.38 (1/1)]
g/mouse. The C3(1/1) mice always had significantly
greater adiposity (measured as the sum of the four adipose
tissue depots/BW) on both diets [12% 6 2% C3(1/1) vs. 6%
6 1% C3(2/2) on LF diet and 24% 6 2% C3(1/1) vs. 18%
6 1% C3(2/2) on HF diet]. This difference in adipose tissue
was also observed at 48 weeks on the low fat diet although
to a lesser extent (35.3% decrease in total adipose tissue; P ,
0.04, data not shown), whereas there was no difference on the
HF diet.
Leptin levels are highly correlated with adipose tissue
mass and were thus measured in these animals at 10, 14, and
26 weeks on the corresponding diets (Fig. 3). Leptin levels
increased with age and even more so with fat content of the
diet, as previously reported (30, 31, 38), accurately reflecting
increases in adipose tissue mass. The leptin levels were sig-
nificantly reduced in the knockout animals on both diets (LF,
P , 0.01, ANOVA; HF, P , 0.0001, by ANOVA). Leptin levels
were also measured at 32 and 48 weeks of age in a subset of
mice at the time of death and dissection. At 32 weeks there
were significant differences in leptin in the knockout vs. the
wild-type mice on the LF diet [8.95 6 2.0 (n 5 4) vs. 18.7 6
5.6 (n 5 5) ng/ml; P , 0.05] and on the HF diet [17.4 6 1.8
(n 5 3) vs. 32.5 6 3.5 (n 5 4) ng/ml; P , 0.025], which
corresponded to the reduced adipose tissue mass (Fig. 2). By
48 weeks of age, although the differences were maintained
on a LF diet, on the HF diet the differences between C3(1/1)
and C3(2/2) were no longer evident, again consistent with
the adipose tissue weights [LF diet, 20.6 6 6.1 C3(2/2) (n 5
3) vs. 27.3 6 5.7 C3(1/1) (n 5 3); HF diet, 60.4 6 5.5 C3(2/2)
(n 5 3) vs. 62.3 6 5.2 C3(1/1) (n 5 3) ng/ml leptin].
Leptin levels correlated very closely with the size of all
adipose tissue depots (r 5 0.799, 0.728, 0.909, and 0.844 for
inguinal, pectoral, perirenal, and gonadal, respectively) as
well as with total adipose tissue (r 5 0.911; n 5 24) for
combined data of female mice at 32 and 48 weeks, LF and HF
diets, and C3(2/2) and (1/1). However, the highest cor-
relation was with body weight (r 5 0.934, by Pearson cor-
relation). The relationship between body weight and leptin
levels (which is an indicator of adiposity) in both the
C3(1/1) and C3(2/2) groups for all mice from 10–48
weeks of age was also significantly different. The data show
that there is a linear relationship between body weight and
FIG. 1. Growth curves in mice on LF
and HF diets. Knockout C3(2/2) mice
(filled circles, dotted line) and wild-type
C3(1/1) mice (open squares, solid line)
on LF (10% Cal; left panel) and HF (40%
Cal diet; right panel) diets were
weighed twice weekly from 4–26 weeks
of age. The diets were started at 10
weeks of age. The data are given as the
mean 6 SEM with C3(2/2) (LF, n 5 12;
HF, n 5 11) and C3(1/1) (LF, n 5 8; HF,
n 5 6). Statistical differences were de-
termined by two-way repeated mea-
sures ANOVA.
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leptin in both sets of animals [r2 5 0.85, slope 5 1.08 6 0.123,
x-intercept 5 20.1, n 5 36 for C3(1/1); r2 5 0.70, slope 5
1.36 6 0.095, x-intercept 5 18.9, n 5 38 for C3(2/2)]. For any
given body weight, leptin levels were significantly lower in
C3(2/2) mice (P , 0.0001).
Food intake was also measured and relative energy intake
calculated as caloric intake per g BW over the 16-week diet
period. Despite the decreased body weight in the knockout
mice, there was no decrease in food intake noted for the
C3(2/2) mice on the low fat diet [96.8 6 1.1 C3(1/1) vs.
97.9 6 1.4 C3(2/2) cal/week]. On the high fat diet, the food
intake of the knockout mice increased markedly compared
with that of the wild-type mice after 14 weeks of age, and this
difference was maintained for the duration of the study (Fig.
4, left panel). The average energy intake was 107.3 6 1.8
cal/week C3(1/1) vs. an energy intake of 125.9 6 2.3 cal/
week in the C3(2/2), an average increase of 17.5 6 2.1% (P ,
0.0001). Energy intake (in calories) per g BW was substan-
tially greater (and therefore less efficient) in the knockout
animals than in the wild-type mice on both diets, but espe-
cially the HF [Fig. 4, right panel; increase, 33.2 6 2.7% cal/g
BW; C3(2/2) vs. C3(1/1), P , 0.0001), and over the 16-
week period, the average calories per week/g increase in BW
was substantially greater in the C3(2/2) mice on both LF
[172 6 20 C3(1/1) vs. 196 6 32 C3(2/2); 14% increase] and
HF [160 6 30 C3(1/1) vs. 192 6 36 C3(2/2); 20% increase].
To determine whether this phenotype could be attributed
to a lack of intestinal absorption, fecal fat content was ana-
lyzed in a subset of mice (16–20 weeks old) on a chow diet
equal in fat content to the LF diet. There was no change in
FIG. 2. Adipose tissue weights in mice
on LF and HF diets. The adipose tissue
weights of female knockout C3(2/2)
mice (filled bars) and wild-type C3(1/1)
mice (open bars) on a LF [10% Cal diet;
left panel; C3(2/2), n 5 4; C3(1/1), n 5
5] or a HF [40% Cal diet; right panel;
C3(2/2), n 5 3; C3(1/1), n 5 4] were
measured at 32 weeks of age, and the
data are represented as the mean 6
SEM. Ing, Inguinal; Pect, pectoral; Peri,
perirenal; Gonad, gonadal; BAT, brown
adipose tissue. **, P , 0.001; *, P , 0.05
[C3(2/2) vs. C3(1/1)].
FIG. 3. Plasma leptin levels in mice on
LF and HF diets. Plasma leptin levels at
10, 14, and 26 weeks were measured in
wild-type C3(1/1) (open squares) and
knockout C3(2/2) (filled circles) on the
LF and HF diets (left and right panels,
respectively). The sample sizes are five
and three for the C3(2/2) and four and
four for the C3(1/1) on the LF and HF
diets, respectively. Results are shown
as the mean 6 SEM, and statistical dif-
ferences were measured by two-way re-
peated measures ANOVA.
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the fecal fat weight [5.7 6 0.5% vs. 6.1 6 1.0% on chow diet
(n 5 5 and 3) and 11.3 6 1.1% vs. 10.0 6 0.2% (wt/wt; n 5
3 and 2) after fat load for C3(2/2) vs. C3(1/1) mice, re-
spectively] or fecal lipid profile on TLC (data not shown).
Fasting plasma parameters were measured as shown in
Table 1. There was no significant difference in fasting plasma
triglyceride, cholesterol, or nonesterified fatty acid between
C3(1/1) and C3(2/2), although in both there was an age-
dependent increase in cholesterol and decrease in non-
esterified fatty acids (NEFA) as noted previously (39, 40).
Interestingly, glucose and insulin were significantly de-
creased in the C3(2/2) as well as the glucose 3 insulin
product, and these differences were more marked on the HF
diet. The correlation between insulin and glucose (all ages
and diets) indicated that for any given concentration of in-
sulin, glucose levels were always lower in the C3(2/2) (P ,
0.002).
The glucose levels were investigated further with a glucose
tolerance test in a subset of mice at 30 weeks of age (after 4.5
months on LF or HF diet). The glucose area under the curve
(AUC) increased slightly on the HF fat diet vs. the LF diet, but
there was no significant difference between the C3(1/1) and
C3(2/2) (Table 2). What was striking, however, was that se-
rum insulin in the C3(2/2) mice was markedly lower, both
fasting (Table 1) and after the glucose tolerance test, as shown
by the insulin AUC even on the HF diet (Table 2).
In the early postprandial period adipose tissue hormone-
sensitive lipase is inhibited. Both insulin and ASP have been
shown to inhibit hormone-sensitive lipase (8). We therefore
examined the mice for changes in plasma NEFA and triglyc-
eride postprandially after a fat load of 400 ml olive oil at 14
and 26 weeks of age (Table 3). At 14 weeks of age, there was
no difference in triglyceride AUC between C3(1/1) and
C3(2/2) on either LF or HF diet. However, at 26 weeks of
age, on both LF and HF, the triglyceride AUC was reduced
in C3(2/2) vs. C3(1/1) (Table 3). With regard to the NEFA,
although there was no significant difference in fasting NEFA,
there was an increase in NEFA AUC in the C3(2/2) vs.
C3(1/1), especially at 26 weeks (Fig. 5, left panel). As shown
in Fig. 5, right panel, there was also a consistent drop in NEFA
at 1 h postprandially in the C3(1/1) mice on both LF and
HF diets (HF, 224.0 6 8.5%; HF, 232.3 6 11.3%) at 4 months
on the diet (26 weeks of age). This drop was absent in the
C3(2/2) mice (average 1 h change: LF, 1.2 6 7.2%; HF, 2.4 6
8.6%).
Thus, in the female mice significant decreases were ob-
served in body weight, adipose tissue, leptin levels, and food
efficiency, and moderate changes were found in insulin, glu-
cose, and fatty acid metabolism.
Discussion
In the present report, the ASP phenotype in the female
C3(2/2) mice was characterized by marked decreases in
adipose tissue, body weight, plasma leptin concentrations,
and food efficiency with moderate changes in glucose, in-
sulin, and postprandial NEFA. In male mice, however, the
changes in adipose tissue, body weight, leptin, and food
efficiency, although significant, were far less pronounced
than those in the females, but the NEFA increases were
greater (our unpublished observations). On the other hand,
postprandial lipemia was greatly increased in the male
C3(2/2) mice, a phenomenon that we have seen previously
in young mice (22), but which was strikingly absent from
female mice in the present study at any age or diet stage. This
gender-specific difference may be due to two factors: 1) the
greater reservoir of fat tissue in females vs. males as noted
previously (41), and 2) the greater insulin sensitivity in fe-
males vs. males in mice (40, 42). Both of these would con-
tribute to enhanced lipoprotein lipase mass and activity and
enhanced postprandial clearance, as noted in rodents (43)
and humans (44). In general, gender-specific phenotype pen-
etrance is not uncommon in transgenic mice.
We would hypothesize that the increased postprandial
FIG. 4. Food intake and food efficiency
on HF diets in wild-type and knockout
mice. Food was weighed three times
weekly from the age of 10–26 weeks and
expressed as calories consumed per
week (left panel) and food intake per g
BW (calories consumed per week per g
BW; right panel) for the wild-type
C3(1/1) (open squares; n 5 6) and
knockout C3(2/2) (filled circles; n 5 11)
as the average 6 SEM. Differences be-
tween wild-type and knockout were de-
termined by two-way repeated mea-
sures ANOVA.
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NEFA would be due to a reduced efficiency of adipose tissue
NEFA trapping due to the lack of ASP. This reduced NEFA
trapping may lead to disturbances that impact on glucose
metabolism. In studies described previously, when delivery
of NEFA to peripheral tissues is disrupted (with a targeted
lipoprotein lipase knockout), fasting glucose is proportion-
ally lower (45). Similarly, when GLUT4 is overexpressed in
adipose tissue, this enhances glucose utilization at the ex-
pense of fatty acids (46). Thus, NEFA and glucose metabo-
lism are closely linked, and this may explain the increased
postprandial NEFA but reduced glucose and insulin as well
as increased insulin sensitivity seen in our C3(2/2) mice.
Finally, the decreased glucose and decreased weight gain
may explain the protection against high fat diet-induced
insulin resistance, as both weight gain and increased plasma
glucose contribute directly to insulin resistance (47).
The size of the adipose tissue is regulated by the efficiency
of triglyceride synthesis and storage as well as inhibition of
lipolysis via hormone-sensitive lipase. ASP appears to affect
both of these processes in vitro. In the present studies, the lack
of ASP in female mice results in decreased body weight and
adipose tissue mass, implicating ASP not only in the effi-
TABLE 1. Fasting parameters measured in plasma
Basal chow Low fat High fat Low fat High fat
Age (weeks) 10 14 14 26 26
n (6/10) (6/10) (10/11) (6/11) (9/11)
TG
1/1 54.5 6 1.8 46.8 6 5.3 44.2 6 6.1 44.0 6 3.6 50.0 6 6.1
2/2 54.5 6 4.6 41.4 6 2.7 50.8 6 5.6 37.5 6 2.7 45.0 6 3.1
Chol
1/1 56.6 6 7.0 64.3 6 7.1 84.8 6 17.3 79.5 6 7.3 99.9 6 11.1
2/2 57.6 6 3.9 68.8 6 6.3 65.1 6 4.3 83.4 6 6.8 97.3 6 15.0
NEFA
1/1 0.91 6 0.23 0.43 6 0.06 0.43 6 0.06 0.37 6 0.05 0.31 6 0.06
2/2 1.54 6 0.41 0.54 6 0.06 0.37 6 0.04 0.29 6 0.03 0.29 6 0.03
Glu
1/1 105.6 6 7.3 100.5 6 8.1 102.5 6 6.3 100.9 6 10.0 105.2 6 7.9
2/2 90.8 6 3.2a 89.4 6 6.8 89.4 6 2.9a 96.1 6 3.5 102.2 6 5.8
Ins
1/1 0.19 6 0.03 0.19 6 0.02 0.19 6 0.03 0.30 6 0.04 0.51 6 0.05
2/2 0.20 6 0.01 0.21 6 0.02 0.23 6 0.02 0.22 6 0.02a 0.28 6 0.03a
Glu 3 Ins
1/1 22.9 6 2.4 19.2 6 1.7 21.0 6 3.3 29.2 6 3.8 54.1 6 7.9
2/2 18.2 6 1.6a 18.7 6 3.2 20.3 6 1.8 21.7 6 2.2a 30.7 6 4.4a
Fasting plasma parameters were measured in knockout C3(2/2) and wild type C3(1/1) mice at 10, 14, and 26 weeks of age on low fat (10%
Cal) and high fat (40% Cal) diets. Data are the mean 6 SEM. TG, Triglyceride (milligrams per dl); Chol, cholesterol (milligrams per dl); NEFA,
nonesterified fatty acid (millimolar concentrations); Glu, glucose (milligrams per dl); Ins, insulin (nanograms per ml); Glu 3 Ins, the product
of glucose and insulin concentrations. The sample size is displayed at the top of the columns for wild-type C3(1/1) and C3(2/2) mice,
respectively.
a P , 0.05, comparing between genotypes within age groups.
TABLE 2. Postprandial glucose area under the curve after a glucose tolerance test
Glucose tolerance test
Low fat High fat
C3(1/1) C3(2/2) C3(1/1) C3(2/2)
n (5) (2) (3) (3)
Glucose AUC (mg/dlzh) 229 6 8.3 237 6 11.4 252 6 57 327 6 33
Insulin AUC (mg/dlzh) 1.63 6 0.19 0.81 6 0.03a 1.63 6 0.14 0.75 6 0.01a
Results are given as the postprandial glucose area under the curve (AUC) and insulin area under the curve (AUC) after a glucose tolerance
test. The data shown are for knockout C3(2/2) and wild-type C3(1/1) mice at 30 weeks of age (4 months on diet) for the glucose tolerance test.
The diets are low fat (10% Cal) and high fat (40% Cal). Data are represented as the mean 6 SEM. The sample size (n) is displayed at the top
of the columns for C3(1/1) and C3(2/2) mice, respectively.
a P , 0.005 for C3(2/2) vs. C3(1/1).
TABLE 3. Postprandial triglyceride area under the curve after an oral fat load
Oral fat load
Low fat High fat
C3(1/1) C3(2/2) C3(1/1) C3(2/2)
n (6) (10) (10) (10)
14 weeks old 441.4 6 62.5 418.8 6 91.1 476.8 6 78.3 564.5 6 105.3
26 weeks old 563.1 6 76.8 330.2 6 22.0a 652.2 6 113.8 553.6 6 56.1
Results are given as the postprandial triglyceride area under the curve (AUC) after an oral fat load of 400 ml olive oil, as described in Materials
and Methods. The data shown are for knockout C3(2/2) and wild-type C3(1/1) mice at 14 and 26 weeks of age (4 months on diet). The diets
are low fat (10% Cal) and high fat (40% Cal). Data are given as the mean 6 SEM. The sample sizes are displayed at the top of the columns for
wild-type C3(1/1) and C3(2/2) mice, respectively.
a P , 0.003 significant difference between mice comparing C3(1/1) to C3(2/2).
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ciency of NEFA trapping (48, 49) but also in the regulation
of adipose tissue size. As mice age, body growth diminishes,
and adipose tissue stores normally accumulate. With the
added input of a HF diet, this overcomes the inefficiency of
the adipose tissue seen in the C3(2/2) mice, so that grad-
ually the differences in adipose tissue mass between
C3(2/2) and C3 (1/1) mice are reduced. This decrease in
adiposity could be due to a selective reduction in gastroin-
testinal fat absorption, but malabsorption was ruled out be-
cause there were no changes in fecal lipid content or lipid
composition. As the delivery of fat into the system is normal,
and postprandial lipemia is similar in C3(1/1) and
C3(2/2) mice, we postulate that the reduction in adipose
tissue size is a consequence of reduced storage of dietary
triglyceride (through effects on esterification enzymes)
and/or enhanced lipolysis of adipose tissue triglyceride. The
lack of ASP is consistent with changes in both, as ASP is able
to affect both processes.
The lack of ASP not only disrupts adipose tissue balance
and NEFA/glucose metabolism (as described above), but
also appears to alter overall energy metabolism. This is ex-
emplified by the changes in plasma leptin concentration and
feeding behavior/body weight balance. The simplest expla-
nation for the reduced plasma leptin is that it is a conse-
quence of reduced adipose tissue mass, as leptin is highly
correlated to adipose tissue mass and body weight (38).
However, the correlation analysis suggested that the leptin
levels were decreased more than could be explained by the
decreased body weight, and this occurred despite the in-
creased food intake, which is an important determinant of
leptin production (24, 26). An altered set-point for leptin to
body weight has also been demonstrated in b3-adrenergic
knockout mice (50). It may be that ASP causes an indirect
effect on leptin via the changes in plasma glucose and insulin,
as both of these affect leptin levels (25, 51, 52), or ASP may
have an as yet undefined direct effect on leptin secretion in
adipose tissue.
The consequences of the decreased leptin are increased
eating behavior. However, at the same time that the caloric
intake/body weight increases, there must be simultaneous
nutrient repartitioning into tissues other than adipose tissue
or the body weight in C3(2/2) would be increased relative
to that in wild-type mice. The most likely key target tissues
would be muscle and brown adipose tissue, and these issues
are now being explored.
There are other instances of leanness in murine models
exhibiting moderate (53–55) or dramatic (37, 56, 57) losses in
adipose tissue. Mice with major adipose tissue reductions
demonstrated increased levels of insulin, glucose, and de-
creased leptin (56, 57). Plasma NEFA levels were unchanged
(56) or increased (37). By contrast, with moderate losses of
adipose tissue (similar to our mice), there was little change
from wild-type mice in fasting plasma cholesterol, triglyc-
eride, NEFA, insulin, and glucose and no evidence of insulin
resistance (53). Interestingly, in the aP2/diptheria toxin
white adipose tissue ablation mouse (56), adipose tissue re-
duction only developed postmaturation of the fat pads (after
8 weeks of age) similar to our C3(2/2) murine model, sug-
gesting that it is at the point of puberty and adipose matu-
ration that these differences become apparent. In the protein
kinase A subunit knockout (53), females were predominantly
affected over males, again similar to the C3(2/2) mice pre-
sented here. Our mice have reduced leptin levels, which may
suggest increased leptin sensitivity, resulting in increased
thermogenesis. Consequently, food intake (hyperphagia)
may increase to compensate. Hyperphagia and reduced ad-
ipose tissue mass were also observed in both the protein
kinase A subunit knockouts (53) and white adipose tissue
ablation mice (56).
Adipose tissue loss in humans can also produce metabolic
consequences similar to those seen in the C3(2/2) mice. In
postobese women there appears to be a drive to regain body
weight and reestablish the set-point of adiposity. Increased
lipoprotein lipase activity is observed (58), and in some stud-
ies greater insulin sensitivity was reported with weight loss
(59). Lower insulin levels (60), enhanced triglyceride clear-
ance (Faraj, M., K. Cianflone, and A. D. Sniderman, personal
communication), reduced glucose levels (61), reduced adi-
FIG. 5. Increases in NEFA AUC and
1 h postprandial drop after an oral fat
load. The plasma fatty acid concentra-
tion was measured at 0, 1, 2, 3, 4, and 6 h
after an oral fat load. The AUC for
NEFA was determined over the whole
time course, and the percent change rel-
ative to basal NEFA was calculated (left
panel). The percent drop in NEFA at 1 h
vs. the basal (time zero) value was also
calculated (right panel). Basal NEFA
concentrations are given in Table 1.
Data are shown for C3(2/2) (filled bars)
and C3(1/1), (open bars) for mice on LF
(10%) and HF (40%) diets. *, P , 0.05;
**, P , 0.01.
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pose tissue mass and reduced serum leptin (62, 63) have been
observed in postobese humans. In many ways, the descrip-
tion is similar to our C3(2/2) mice.
Human genetic C3 deficiency is extremely rare, with only
20 cases reported to date in the literature (64). Wetsel et al.
indicated that these “C3-deficient individuals do not appear
to display increased predisposition to hyperlipidemia or cor-
onary artery disease” (65); however, in the review cited (64),
no lipid or lipoprotein information is provided. Complement
C3 deficiencies are commonly associated with membrano-
proliferative glomerulonephritus, partial lipodystrophy, and
occasionally systemic lupus erythematosus symptoms (re-
viewed (64, 66–69). Unfortunately, the majority of these pa-
tients were examined from an immunological standpoint,
and we have been unable to find any detailed lipid and/or
lipoprotein analyses of patients with C3 deficiency.
The reduced adiposity in the female C3 knockout mice
resembles the phenotype of acquired partial lipodystrophy
seen in humans. Partial lipodystrophy may be classified as
congenital or acquired. The congenital form often manifests
in childhood, affects primarily females, and is associated
with hyperlipidemia, hyperinsulinemia, and abnormal glu-
cose tolerance (70–72). Acquired PLD occurs primarily in
adults, and there is little documentation of lipid and glucose
profiles. The acquired form affects both males and females.
Of note, it is associated specifically with hypocomple-
mentemia of C3 (66) due to enhanced catabolism as well as
reduced biosynthesis of C3 (73). This enhanced catabolism is
the consequence of the presence of a C3 nephritic factor,
which acts as an autoantibody, stabilizing the C3 convertase
against spontaneous decay and enhancing C3 breakdown
and clearance (74), thus specifically affecting the proximal
portion of the alternate complement pathway. In a review of
21 cases with acquired partial lipodystrophy, 80.9% demon-
strated markedly reduced complement C3 concentrations
(66). Our murine model demonstrates similarities to humans
with acquired partial lipodystrophy, as evidenced by de-
pleted C3 levels and reduced adipose tissue.
In summary, ASP has been shown previously to play a role
postprandially in both humans and mice. The present study
demonstrates that a lack of ASP has clear effects on adiposity,
energy metabolism, and adipose metabolism in female mice.
In the future, the ASP system may represent a potential
pharmacological target for reducing obesity.
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